[HTML][HTML] Glomerulosclerosis and progression: Effect of subantihypertensive doses of α and βblockers

K Amann, A Koch, J Hofstetter, ML Gross, C Haas… - Kidney international, 2001 - Elsevier
K Amann, A Koch, J Hofstetter, ML Gross, C Haas, SR Orth, H Ehmke, LC Rump, E Ritz
Kidney international, 2001Elsevier
Glomerulosclerosis and progression: Effect of subantihypertensive doses of α and
βblockers. Background Uremia is characterized by inadequately increased sympathetic
activity. Sympathetic overactivity is involved in the genesis of hypertension in uremia, but its
potential role on progression has not been well investigated. To address this issue, the effect
of subantihypertensive doses of an α blocker and a βblocker, and their combination on renal
morphology and on albuminuria were investigated in the model of the subtotally …
Glomerulosclerosis and progression: Effect of subantihypertensive doses of α and βblockers.
Background
Uremia is characterized by inadequately increased sympathetic activity. Sympathetic overactivity is involved in the genesis of hypertension in uremia, but its potential role on progression has not been well investigated. To address this issue, the effect of subantihypertensive doses of an α blocker and a βblocker, and their combination on renal morphology and on albuminuria were investigated in the model of the subtotally nephrectomized rat.
Methods
Male Sprague-Dawley rats were subjected to surgical ablation (SNX) or sham operation (sham). Three days after surgery groups were treated either with phenoxybenzamine (PBZ, 5 mg/kg body weight/day), metoprolol (MET, 150 mg/kg body weight/day) or their combination (PBZ 2.5 mg/kg body weight/day + MET, 50 mg/kg body weight/day). Renal morphology was evaluated after 12 weeks by quantitative histology, immunohistochemistry, and electron microscopy. Urine albumin excretion and kidney endothelin-1 (ET-1), platelet-derived growth factor (PDGF), and transforming growth factor-β(TGF-β) mRNA expression were assessed.
Results
Systolic blood pressure was significantly higher in all SNX groups compared with sham-operated controls with no difference in the SNX groups. The number of glomeruli per left kidney was reduced from 30,904 ± 3212 to 17,480 ± 2341 by SNX (-43.5%). Mean glomerular volume increased from 2.63 ± 0.7 in untreated sham operated to 4.11 ± 0.48 μm3 × 106 in untreated SNX (56.3%). The glomerulosclerosis index did not change in SNX + PBZ rats, but was significantly lower in SNX + MET (0.56 ± 0.14) and particularly SNX + PBZ + MET rats (0.49 ± 0.11) than in untreated SNX (0.74 ± 0.24). Glomerular capillary length density (LV) as a sensitive index of capillary obliteration was significantly lower in SNX and almost normalized in the three intervention groups. The same was true for the mean podocyte number per glomerulus. Glomerular ultrastructure in SNX was largely preserved by all treatments. The albumin excretion rate was significantly higher in untreated SNX than in sham; it was significantly lower in all treated SNX groups.
Conclusion
The beneficial effect of non-hypotensive doses of α and βblockers and their combination on renal morphology and albuminuria in the model of renal ablation argue for a blood pressure-independent role of sympathetic overactivity in the genesis of progression. In addition, the beneficial effect of adrenergic receptor blockade indicates that a substantial part is not mediated by sympathetic cotransmitters such as adenosine 5′-triphosphate (ATP) and neuropeptide Y (NPY).
Elsevier